SEC Form 4 · accession 0001013606-19-000021
ENDOLOGIX INC /DE/ · ELGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vaseem Mahboob
Officer — Chief Financial Officer
Period of report
Dec 30, 2018
Accepted (ET)
Jan 2, 2019 · 9:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001013606
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 30, 2018 | A | 470,115 | $0.00 | A | 616,927 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to PurchaseF2 | $0.7445 | Dec 30, 2018 | A | 225,621 | A | Dec 30, 2019 | Dec 30, 2028 | Common Stock | 225,621 | 225,621 | D |
Explanation of responses
- F1(i) 201,478 time-based restricted stock units (RSUs) vest in two equal annual installments on December 30, 2019 and December 30, 2020, and (ii) 268,637 RSUs vest as to 100% of the underlying shares on December 30, 2021, provided that the vesting of the RSUs shall be subject to acceleration based on the achievement of specified Company and/or individual performance criteria to be approved by the Company's compensation committee. All RSUs granted shall settle in shares of common stock on each of the dates indicated.
- F2100% of the option award shall vest on December 30, 2019.